Arrowhead Pharmaceuticals (ARWR) EBITDA (2003 - 2026)
Arrowhead Pharmaceuticals (ARWR) EBITDA from Sep 30, 2003 to Mar 31, 2026. The TTM Arrowhead Pharmaceuticals (ARWR) EBITDA is -$198M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Arrowhead Pharmaceuticals (ARWR) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +99.89% |
| 3 Years TTM | +11.81% |
| 5 Years TTM | +11.90% |
| 10 Years TTM | +9.68% |
| All Time TTM | +29.62% |
Annual EBITDA change of Arrowhead Pharmaceuticals (ARWR)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$135M | -212.29% |
| 2025 | $121M | -120.64% |
| 2024 | -$584M | +200.66% |
| 2023 | -$194M | +14.42% |
| 2022 | -$170M | +19.22% |
| 2021 | -$142M | +60.12% |
| 2020 | -$89M | -239.24% |
| 2019 | $64M | +430.65% |
| 2018 | $12M | -191.21% |
| 2017 | -$13M | +9.18% |
| 2016 | -$12M | -37.23% |
| 2015 | -$19M | -14.70% |
| 2014 | -$23M | +112.42% |
| 2013 | -$11M | +130.59% |
| 2012 | -$4.61M | -51.78% |
| 2011 | -$9.56M | +71.94% |
| 2010 | -$5.56M | -71.21% |
| 2009 | -$19M | -29.11% |
| 2008 | -$27M | -11.30% |
| 2007 | -$31M | +53.86% |
| 2006 | -$20M | +196.58% |
| 2005 | -$6.73M | +797.33% |
| 2004 | -$750K | +650.00% |
| 2003 | -$100K | N/A |
Comparison Arrowhead Pharmaceuticals (ARWR) five years EBITDA CAGR with competitors
Arrowhead Pharmaceuticals (ARWR) five years EBITDA CAGR is 11.90%.